Research progress on the etiology and pathogenesis of pancreatic cancer: a narrative review
-
By
-
Meitong Guo
-
Qi Han
-
Zixi Wang
-
Dong Ya
-
Xiaoyan Wang
-
June 11, 2026
-
Clinical Scorecard: Advancements in Understanding the Causes and Mechanisms of Pancreatic Cancer: A Comprehensive Review
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | |
| Target Population | Patients diagnosed with pancreatic cancer, predominantly aged 40-85 years (source needed). |
| Care Setting | Clinical oncology and gastroenterology settings (source needed). |
Key Highlights
- 5-year survival rate of merely 13% (source needed).
- Over 80% of patients diagnosed at an advanced stage (source needed).
- Projected increase in incidence by more than 30% by 2040 (source needed).
- 90% of cases are adenocarcinoma (source needed).
- Major precursor lesions include PanIN, IPMN, and MCN (source needed).
Guideline-Based Recommendations
Diagnosis
- Current diagnostic strategies are limited; early symptoms are often non-specific (source needed).
Management
- Clinical treatment strategies include surgical resection, chemotherapy, radiotherapy, molecular targeted therapy, and biological immunotherapy (source needed).
Monitoring & Follow-up
- Clinical surveillance and intervention may be possible for high-grade dysplasia and invasive carcinoma (source needed).
Risks
- Risk factors include smoking, alcohol consumption, obesity, diabetes, chronic pancreatitis, and genetic mutations (source needed).
Patient & Prescribing Data
Existing treatments have not significantly improved survival outcomes (source needed).
Clinical Best Practices
- Focus on the progression of precancerous lesions for potential early detection (source needed).
- Integrate pathological precursor lesions and driver genes in clinical assessments (source needed).
Related Resources & Content
